Our research centers on deciphering the molecular mechanisms controlling antitumor immunity, and exploiting knowledge to device new gene- and cell-based cancer immunotherapies.
We have two active research directions:
Zhu Y.*, Smith DJ*, Zhou Y, Li YR, Yu J, Lee D, Wang Y-C, Di Biase S, Wang Xi, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu GR, Ribas A, Kohn DB, Witte ON, and Yang L. (Co-first authors). Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell Stem Cell. 2019, 25(4):542-557. Epub 2019 Sept 5. [Link][PDF][CSC Highlight]
Our JEM paper reporting creatine uptake regulation of CD8 T cell immunity is featured on UCLA News and other media.
Our Cell Stem Cell paper reporting HSC-engineering iNKT cell cancer therapy is featured on UCLA News and other media. [PDF][UCLA
Dr. Lili Yang receives the Outstanding New Investigator Award from the American Society of Gene & Cell Therapy (ASGCT). [PDF][Link]
Di Biase S*, Ma X*, Wang X, Yu J, Wang Y-C, Smith DJ, Zhou Y, Li Z, Kim YJ, Clarke N, To A, and Yang L. (Co-first authors). Creatine uptake regulates CD8 T cell antitumor immunity. J Exp Med. 2019, 216(12): 2869-2882. Epub 2019 Oct 18. [